Clinical studies of prostatic cancer imaging with radiolabeled antibodies against prostatic acid phosphatase.
Conventional antibodies against prostatic acid phosphatase, labeled with iodine-131, have been administered to patients with prostatic carcinoma for the external scintigraphic imaging of tumors containing prostatic acid phosphatase (radioimmunodetection). The method has been found to be safe and reliable for imaging of primary tumors and non-bone metastases, even differentiating between lung tumors of prostatic and pulmonary origin.
D000135:Acid Phosphatase / Q000276:immunology*; D000818:Animals; D000906:Antibodies / Q000008:administration & dosage*; D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D002277:Carcinoma / Q000000981:diagnostic imaging* / Q000556:secondary; D006041:Goats / Q000276:immunology; D006801:Humans; D007457:Iodine Radioisotopes; D007553:Isotope Labeling; D008175:Lung Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D008297:Male; D011467:Prostate / Q000201:enzymology; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D011817:Rabbits / Q000276:immunology; D011877:Radionuclide Imaging; D012709:Serum Albumin; D013670:Sodium Pertechnetate Tc 99m; D013667:Technetium; D013668:Technetium Tc 99m Aggregated Albumin
D000906:Antibodies; D007457:Iodine Radioisotopes; D012709:Serum Albumin; D013668:Technetium Tc 99m Aggregated Albumin; D013667:Technetium; D013670:Sodium Pertechnetate Tc 99m; D000135:Acid Phosphatase